Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xiaohong Pu"'
Publikováno v:
Economic Analysis and Policy. 78:273-289
Publikováno v:
Human Pathology. 115:37-46
Summary In addition to hepatoid adenocarcinoma (HAC), gastric adenocarcinoma with enteroblastic differentiation (GAED) and common adenocarcinoma (COM) could also show hepatoid differentiation, which presents a poor prognosis. To elucidate the histoge
Autor:
Xiaohong Pu, Yao Fu, Qi Sun, Lin Li, Jun Chen, Hongyan Wu, Attigah Samuel Doe Kwasi, Ziyan Ma, Xiangshan Fan, Beicheng Sun
Publikováno v:
SSRN Electronic Journal.
Autor:
Jiawei Xie, Xiaohong Pu, Jian He, Yudong Qiu, Cheng Lu, Wei Gao, Xiangxue Wang, Haoda Lu, Jiong Shi, Yuemei Xu, Anant Madabhushi, Xiangshan Fan, Jun Chen, Jun Xu
Publikováno v:
Computers in Biology and Medicine. 146:105520
Intrahepatic cholangiocarcinoma (ICC) is cancer that originates from the liver's secondary ductal epithelium or branch. Due to the lack of early-stage clinical symptoms and very high mortality, the 5-year postoperative survival rate is only about 35%
Autor:
Xi-Wei Ding, Xiaohong Pu, Liang Mao, Jun Yang, Yudong Qiu, Qing Ye, Hongyan Wu, Jiong Shi, Qin Huang, Xiangshan Fan, Jun Chen
Publikováno v:
Human Pathology. 76:100-109
Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer rarely curable by surgery that is increasing rapidly in incidence. Chromosomal translocations and amplifications of the fibroblast growth factor receptor 2 (FGFR2) locus are p
Publikováno v:
Pathology - Research and Practice. 216:153116
Background As more and more molecular markers have been identified in Intrahepatic Cholangiocarcinoma (ICC), target treatments are promising all around the world. However, geographical and ethnic variations in the ICC epidemiology suggest different g
Publikováno v:
Pathology - Research and Practice. 211(6):421-425
It has been proven that chromosome 17 centromere (CEP17) amplification causes misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ hybridization (FISH) results, precluding anti-HER2-based therapy in some patients with